信迪利单抗联合白蛋白结合型紫杉醇化疗二线治疗晚期胃癌的疗效研究  

Efficacy Study of Sintilimab Combined with Albumin-Bound Paclitaxel in Second-line Treatment of Advanced Gastric Cancer

作　　者：席玲玲 XI Lingling(Department of Internal Medicine,Luoyang Petrochemical Hospital,Luoyang Henan 471000,China)

机构地区：[1]洛阳石化医院内三科,河南洛阳471000

出　　处：《临床研究》2024年第12期60-63,共4页Clinical Research

摘　　要：目的探究晚期胃癌患者,在二线治疗中联合应用信迪利单抗、紫杉醇(白蛋白结合型)的价值。方法研究选取洛阳石化医院2021年12月至2023年6月期间收入的62例胃癌晚期患者。按临床化疗方案不同将其划分为研究组(n=31)采用信迪利单抗联合紫杉醇(白蛋白结合型)、对照组(n=31)单纯应用紫杉醇(白蛋白结合型),比较两组客观缓解率、免疫功能指标、肝肾功能指标、生存质量及不良反应差异。结果研究组客观缓解率(45.16%)高于对照组(19.35%),差异有统计学意义(P<0.05);治疗前,两组免疫指标比较,差异无统计学意义(P>0.05);治疗后,两组免疫指标均降低,且研究组均高于对照组,差异有统计学意义(P<0.05);治疗前,两组胃癌量表评分比较,差异无统计学意义(P>0.05),治疗后,两组胃癌量表评分提高,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组肝肾功能指标、不良反应发生情况比较,差异无统计学意义(P>0.05)。结论信迪利单抗联合白蛋白结合型紫杉醇化疗,在二线治疗晚期胃癌中的临床疗效较为理想,能够进一步改善患者免疫指标水平,提升生存质量,同时不会增加肝肾损伤等不良反应,具有临床应用价值。Objective To explore the value of combining sintilimab and albumin-bound paclitaxel in the second-line treatment of patients with advanced gastric cancer.Methods A total of 62 patients with advanced gastric cancer who were admitted to Luoyang Petrochemical Hospital between December 2021 and June 2023 were selected.Based on different chemotherapy regimens,patients were divided into a study group(n=31)receiving sintilimab combined with albumin-bound paclitaxel and a control group(n=31)receiving only albumin-bound paclitaxel.The two groups were compared for objective response rate,immune function indicators,liver and kidney function indicators,quality of life,and adverse reactions.Results The objective response rate in the study group(45.16%)was significantly higher than that in the control group(19.35%)(P<0.05).Before treatment,there were no significant differences in immune indicators between the two groups(P>0.05).After treatment,the immune indicators decreased in both groups,with the study group showing significantly higher levels than the control group(P<0.05).There were no significant differences in gastric cancer scale scores before treatment(P>0.05),but after treatment,the scores improved in both groups,with the study group scoring significantly higher than the control group(P<0.05).No significant differences were found between the two groups in liver and kidney function indicators or the occurrence of adverse reactions after treatment(P>0.05).Conclusion The combination of sintilimab and albumin-bound paclitaxel in second-line treatment for advanced gastric cancer demonstrates favorable clinical efficacy,improves immune function levels,enhances quality of life,and does not increase the risk of liver and kidney damage or other adverse reactions,indicating its clinical application value.

关 键 词：信迪利单抗 白蛋白结合型紫杉醇 化疗 二线治疗 胃癌 

分 类 号：R735.2[医药卫生—肿瘤]